                         SEQUENCE LISTING

<110>  UCL Business PLC
 
<120>  Anionic nanocomplexes for nucleic acid delivery

<130>  P027351WO

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cleavable portion of the spacer element peptide B

<400>  1

Arg Val Arg Arg 
1               


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Receptor binding sequence of the cell surface receptor binding 
       component C


<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  The residue at each of these positions can be P or Q

<400>  2

Leu Pro Pro Pro Pro Pro Pro His Lys 
1               5                   


<210>  3
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Oligolysine polycationic nucleic acid binding component

<400>  3

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A linker sequence of the spacer element peptide B


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  6-amino hexanoic acid

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  6-amino hexanoic acid

<400>  4

Xaa Ser Xaa Gly Gly 
1               5   


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A linker sequence of the spacer element peptide B


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  6-aminohexanoic acid

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  6-aminohexanoic acid

<400>  5

Xaa Ser Xaa Gly Ala 
1               5   


<210>  6
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A cleavable sequence and a linker sequence in the spacer element 
       peptide B

<400>  6

Arg Val Arg Arg Gly Ala 
1               5       


<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A cleavable sequence and a linker sequence in the spacer element 
       peptide B

<400>  7

Arg Val Arg Arg Gly Cys 
1               5       


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A cleavable sequence and a linker sequence in the spacer element 
       peptide B


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  6-amino hexanoic acid

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  6-amino hexanoic acid

<400>  8

Arg Val Arg Arg Xaa Ser Xaa 
1               5           


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A cleavable sequence and a linker sequence in the spacer element 
       peptide B


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  6-amino hexanoic acid

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  6-amino hexanoic acid

<400>  9

Arg Val Arg Arg Xaa Ser Xaa Gly Ala 
1               5                   


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A cleavable sequence and a linker sequence in the spacer element 
       peptide B


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  6-amino hexanoic acid

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  6-amino hexanoic acid

<400>  10

Arg Val Arg Arg Xaa Ser Xaa Gly Cys 
1               5                   


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Component of the cell surface receptor binding component C

<400>  11

Tyr Gly Leu Pro His Lys Phe 
1               5           


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Component of the cell surface receptor binding component C

<400>  12

Cys Tyr Gly Leu Pro His Lys Phe Cys Gly 
1               5                   10  


<210>  13
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide 35 for use in accordance with the invention


<220>
<221>  MOD_RES
<222>  (21)..(21)
<223>  6-amino hexanoic acid

<220>
<221>  MOD_RES
<222>  (23)..(23)
<223>  6-amino hexanoic acid

<400>  13

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Arg Val Arg Arg Xaa Ser Xaa Gly Ala Cys Tyr Gly Leu Pro His Lys 
            20                  25                  30          


Phe Cys Gly 
        35  


<210>  14
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide 32 for use in accordance with the invention

<400>  14

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Arg Val Arg Arg Gly Ala Cys Tyr Gly Leu Pro His Lys Phe Cys Gly 
            20                  25                  30          


<210>  15
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide ME27 for use in accordance with the invention

<400>  15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Arg Val Arg Arg Gly Ala Cys Arg Gly Asp Cys Leu Gly 
            20                  25                  


<210>  16
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide Y for use in accordance with the invention

<400>  16

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Gly Ala Cys Tyr Gly Leu Pro His Lys Phe Cys Gly 
            20                  25              


